Correlation Between Inozyme Pharma and Viracta Therapeutics
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Viracta Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Viracta Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Viracta Therapeutics, you can compare the effects of market volatilities on Inozyme Pharma and Viracta Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Viracta Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Viracta Therapeutics.
Diversification Opportunities for Inozyme Pharma and Viracta Therapeutics
0.92 | Correlation Coefficient |
Almost no diversification
The 3 months correlation between Inozyme and Viracta is 0.92. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Viracta Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viracta Therapeutics and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Viracta Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viracta Therapeutics has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Viracta Therapeutics go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Viracta Therapeutics
Given the investment horizon of 90 days Inozyme Pharma is expected to generate 0.63 times more return on investment than Viracta Therapeutics. However, Inozyme Pharma is 1.6 times less risky than Viracta Therapeutics. It trades about 0.0 of its potential returns per unit of risk. Viracta Therapeutics is currently generating about -0.03 per unit of risk. If you would invest 390.00 in Inozyme Pharma on September 14, 2024 and sell it today you would lose (87.00) from holding Inozyme Pharma or give up 22.31% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inozyme Pharma vs. Viracta Therapeutics
Performance |
| Timeline |
| Inozyme Pharma |
| Viracta Therapeutics |
Inozyme Pharma and Viracta Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inozyme Pharma and Viracta Therapeutics
The main advantage of trading using opposite Inozyme Pharma and Viracta Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Viracta Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viracta Therapeutics will offset losses from the drop in Viracta Therapeutics' long position.| Inozyme Pharma vs. Day One Biopharmaceuticals | Inozyme Pharma vs. X4 Pharmaceuticals | Inozyme Pharma vs. Acumen Pharmaceuticals | Inozyme Pharma vs. Mereo BioPharma Group |
| Viracta Therapeutics vs. Puma Biotechnology | Viracta Therapeutics vs. Iovance Biotherapeutics | Viracta Therapeutics vs. Day One Biopharmaceuticals | Viracta Therapeutics vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Complementary Tools
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |